Business Description
Aerie Pharmaceuticals Inc
NAICS : 325412
SIC : 2836
ISIN : US00771V1089
Description
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.51 | |||||
| Equity-to-Asset | -0.44 | |||||
| Debt-to-Equity | -2.06 | |||||
| Debt-to-EBITDA | -109.63 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -2.68 | |||||
| Beneish M-Score | -2.28 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 93.3 | |||||
| 3-Year EBITDA Growth Rate | 67.5 | |||||
| 3-Year EPS without NRI Growth Rate | 33.9 | |||||
| 3-Year FCF Growth Rate | 20.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 19.79 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 123.35 | |||||
| 12-1 Month Momentum % | 56.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.27 | |||||
| Quick Ratio | 1.92 | |||||
| Cash Ratio | 1.29 | |||||
| Days Inventory | 634.48 | |||||
| Days Sales Outstanding | 115.66 | |||||
| Days Payable | 132.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.1 | |||||
| Shareholder Yield % | -10.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.01 | |||||
| Operating Margin % | -12.49 | |||||
| Net Margin % | -17.09 | |||||
| FCF Margin % | 1.23 | |||||
| ROA % | -9.42 | |||||
| ROIC % | -24.26 | |||||
| ROC (Joel Greenblatt) % | -29.37 | |||||
| ROCE % | -8.75 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.36 | |||||
| Price-to-Free-Cash-Flow | 331.52 | |||||
| Price-to-Operating-Cash-Flow | 107.39 | |||||
| EV-to-EBIT | -39.51 | |||||
| EV-to-EBITDA | -298.68 | |||||
| EV-to-Revenue | 4.29 | |||||
| EV-to-Forward-Revenue | 5.24 | |||||
| EV-to-FCF | 348.17 | |||||
| Earnings Yield (Greenblatt) % | -2.53 | |||||
| FCF Yield % | 0.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AERI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aerie Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 213.941 | ||
| EPS (TTM) ($) | -0.77 | ||
| Beta | 0 | ||
| Volatility % | 136.3 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.015357 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 56.8 | ||
| 52-Week Range ($) | 4.81 - 15.37 | ||
| Shares Outstanding (Mil) | 49.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aerie Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aerie Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aerie Pharmaceuticals Inc Frequently Asked Questions
What is Aerie Pharmaceuticals Inc(AERI)'s stock price today?
The current price of AERI is $15.25. The 52 week high of AERI is $15.37 and 52 week low is $4.81.
When is next earnings date of Aerie Pharmaceuticals Inc(AERI)?
The next earnings date of Aerie Pharmaceuticals Inc(AERI) is 2024-08-04 Est..
Does Aerie Pharmaceuticals Inc(AERI) pay dividends? If so, how much?
Aerie Pharmaceuticals Inc(AERI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers